4D Molecular Therapeutics Inc Ordinary Shares FDMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FDMT is a good fit for your portfolio.
News
-
4DMT to Participate in Upcoming Investor Conferences
-
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
-
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
-
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
-
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
-
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
-
4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
-
4DMT to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $12.70
- Day Range
- $12.61–13.38
- 52-Week Range
- $9.49–26.30
- Bid/Ask
- $13.11 / $13.15
- Market Cap
- $560.93 Mil
- Volume/Avg
- 186,734 / 337,666
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.13
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 144
Valuation
|
Metric
|
FDMT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.65 |
Price/Sales | 21.13 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FDMT
|
|---|---|
Quick Ratio | 17.60 |
Current Ratio | 18.07 |
Interest Coverage | — |
Quick Ratio
FDMT
Profitability
|
Metric
|
FDMT
|
|---|---|
Return on Assets (Normalized) | −25.86% |
Return on Equity (Normalized) | −28.60% |
Return on Invested Capital (Normalized) | −30.22% |
Return on Assets
FDMT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bzh | $456.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kpjvmm | $91.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zdmbbf | $89.8 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Rnxdtrc | $40.2 Bil | |
MRNA
| Moderna Inc | Jxnjn | $29.6 Bil | |
ARGX
| argenx SE ADR | Nmt | $26.4 Bil | |
BNTX
| BioNTech SE ADR | Hzfp | $23.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jrjqwz | $21.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ddvfgk | $17.2 Bil | |
INCY
| Incyte Corp | Bmrqfjn | $12.2 Bil |